ACCELERON PHARMA INC. Net Change in Cash
ACCELERON PHARMA INC. reported Net Change in Cash of -$334.70 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2021-11-04
- ACCELERON PHARMA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2021-03-31 was -$215.44M, a 641.18% decline year-over-year.
- ACCELERON PHARMA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2020-03-31 was $39.81M, a 43.48% decline year-over-year.
- ACCELERON PHARMA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2019-03-31 was $70.44M.
- ACCELERON PHARMA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2018-03-31 was -$30.41M, a 345.41% decline year-over-year.
- ACCELERON PHARMA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was $433.27M, a 362.78% increase from fiscal 2019.
- ACCELERON PHARMA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2019 was $93.63M, a 111.02% increase from fiscal 2018.
- ACCELERON PHARMA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2018 was $44.37M, a 44.11% decline from fiscal 2017.
- ACCELERON PHARMA INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2017 was $79.39M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2021-09-30 | -$334.70M 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | -$334.75M 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | -$215.44M 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $433.27M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $492.01M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $45.84M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $39.81M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $93.63M 10-K · filed 2021-02-25 | |||
| 2019-09-30 | $25.49M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $19.56M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $70.44M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $44.37M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $12.74M 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | -$20.56M 10-Q · filed 2019-08-05 | |||
| 2018-03-31 | -$30.41M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $79.39M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | $218.19M 10-Q · filed 2018-10-30 | |||
| 2017-06-30 | $9.96M 10-Q · filed 2018-08-02 | |||
| 2017-03-31 | $12.39M 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | -$6.68M 10-K · filed 2019-02-27 |